Document is current
Any future updates will be listed below
-
Authors
Qian, Juying https://orcid.org/0000-0002-7512-3692
Zhang, Xuelian https://orcid.org/0009-0000-9696-9745
Chen, Jiyan https://orcid.org/0000-0003-1216-9316
Ding, Chunhua https://orcid.org/0000-0003-4381-6723
Yang, Ping https://orcid.org/0000-0001-7960-6248
Qing, Li https://orcid.org/0009-0002-3971-1574
Liu, Yan https://orcid.org/0009-0003-3120-3011
Chen, Si Si https://orcid.org/0009-0003-0281-0824
Ge, Junbo https://orcid.org/0000-0001-9640-8171
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03768427 at ClinicalTrials.govDocuments that mention this clinical trial
LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial
https://doi.org/10.1007/s12325-025-03429-8
-
Funding
Funding for this research was provided by:
Organon
- License Information
-
More Information
Article History
Received: 24 July 2025
Accepted: 5 November 2025
First Online: 19 January 2026
Declarations
:
: Yan Liu is an employee of Organon. Si Si Chen was an employee of Organon (Shanghai) Pharmaceutical Technology Co., Ltd. Juying Qian, Xuelian Zhang, Jiyan Chen, Chunhua Ding, Ping Yang, Li Qing, and Junbo Ge have nothing to disclose.
: This study adhered to the local and/or national regulations, including the International Council for Harmonisation Good Clinical Practice, and was conducted in accordance with the ethics principles of the Declaration of Helsinki. The study protocol was approved by the institutional review board of each site, and written informed consent was obtained from all participants before commencing any study-specific procedure.
